Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Rating of “Reduce” by Analysts

Kodiak Sciences Inc. (NASDAQ:KOD) has been assigned an average rating of “Reduce” from the seven brokerages that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $5.50.

KOD has been the topic of several research reports. Barclays raised their price target on shares of Kodiak Sciences from $2.00 to $3.00 and gave the stock an “underweight” rating in a research note on Monday, April 1st. UBS Group raised their price objective on shares of Kodiak Sciences from $3.00 to $5.00 and gave the stock a “neutral” rating in a research report on Thursday, April 4th.

Kodiak Sciences Stock Performance

Shares of NASDAQ KOD opened at $3.21 on Friday. The company has a market capitalization of $168.59 million, a PE ratio of -0.65 and a beta of 2.15. Kodiak Sciences has a 1 year low of $1.37 and a 1 year high of $9.80. The company’s fifty day moving average price is $5.00 and its 200 day moving average price is $3.72.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.27). On average, equities analysts expect that Kodiak Sciences will post -4.31 EPS for the current year.

Institutional Trading of Kodiak Sciences

Several institutional investors have recently modified their holdings of KOD. SG Americas Securities LLC purchased a new stake in shares of Kodiak Sciences during the 3rd quarter worth approximately $37,000. Acuitas Investments LLC purchased a new stake in shares of Kodiak Sciences during the 3rd quarter worth approximately $265,000. Marquette Asset Management LLC purchased a new stake in shares of Kodiak Sciences during the 3rd quarter worth approximately $54,000. Barclays PLC increased its holdings in shares of Kodiak Sciences by 78.3% in the 3rd quarter. Barclays PLC now owns 63,384 shares of the company’s stock valued at $114,000 after acquiring an additional 27,843 shares during the period. Finally, Monaco Asset Management SAM increased its holdings in shares of Kodiak Sciences by 129.5% in the 3rd quarter. Monaco Asset Management SAM now owns 493,726 shares of the company’s stock valued at $889,000 after acquiring an additional 278,605 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.